|Titre :||Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience (2015)|
|Auteurs :||S. J. HUTCHINSON ; J. F. DILLON ; R. FOX ; S. A. McDONALD ; H. A. INNES ; A. WEIR ; A. McLEOD ; E. J. ASPINALL ; N. E. PALMATEER ; A. TAYLOR ; A. MUNRO ; H. VALERIO ; G. BROWN ; D. J. GOLDBERG|
|Type de document :||Article : Périodique|
|Dans :||International Journal of Drug Policy (Vol.26, n°11, November 2015)|
|Article en page(s) :||1041-1049|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEHEPATITE ; TRAITEMENT ; ACCES AUX SOINS ; USAGER ; PLANIFICATION SANITAIRE ; POLITIQUE ; DIAGNOSTIC
Thésaurus GéographiqueECOSSE ; ROYAUME-UNI
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan – a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of accountable national and local multi-disciplinary multi-agency networks responsible for the planning, development and delivery of services. Initiatives ranged from the introduction of testing in specialist drug services through finger-prick blood sampling by non-clinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan was informed by comprehensive national monitoring systems, indicating the extent of the problem not just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the number advancing to end-stage liver disease and death, and also through compelling modelling work demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting. Achievements include around 50% increase in the proportion of the infected population diagnosed (38% to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to 140); and reversing of an upward trend in the overall number of people living with chronic infection. The Action Plan has demonstrated that a Government-backed, coordinated and invested approach can transform services and rapidly improve the lives of thousands. Cited as "an impressive example of a national strategy" by the Global Commission on Drug Policy, the Scottish Plan has also provided fundamental insights of international relevance into the management of HCV among PWID.
A Government-backed and invested HCV Plan can transform services and improve lives.
Surveillance/research data were crucial in leveraging support for Scotland's Plan.
This Plan has provided fundamental insights into the management of HCV among PWID.
The impact of National Plans on severe liver morbidity should be monitored closely.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK|